Coming soonShelf 036 entries6 published
Growth hormone axis
Peptides that act on growth hormone release, through either the GHRH receptor or the ghrelin receptor. One of them is a licensed medicine; all of them are prohibited in sport.
Entries
On this shelf
| No. | Compound | Parent or target | Evidence | Status |
|---|---|---|---|---|
| 0004 | Tesamorelin44 residues · 5135.9 g/mol | GHRH | Licensed in the US since 2010 | Published |
| 0009 | Ipamorelin5 residues · 711.9 g/mol | Ghrelin receptor | Phase 2, stopped | Published |
| 0010 | CJC-129530 residues · 3647.3 g/mol | GHRH | Two 2006 studies; development stopped | Published |
| 0016 | Sermorelin29 residues | GHRH | Formerly licensed in the US | Published |
| 0024 | Kisspeptin-1010 residues | Kisspeptin receptor | Small human studies | Published |
| 0015 | Epitalon4 residues | Pineal peptide | Mostly Russian studies | Published |
Compare
Side by side
| Tesamorelin | Ipamorelin | CJC-1295 | |
|---|---|---|---|
| Receptor | GHRH receptor | Ghrelin receptor | GHRH receptor |
| Length | 44 residues | 5 residues | 30 residues |
| Lasts | Minutes in blood | Hours (not well established) | 6–8 days (with DAC) |
| Human evidence | Two phase 3 trials | PK study and failed phase 2 | Two short 2006 studies |
| WADA | S2.2.4 | S2.2.4 | S2.2.4 |
Every compound on this shelf is prohibited in sport at all times.
Compare
